Literature DB >> 2465401

Human immunodeficiency viruses: neutralization and receptors.

R A Weiss1, P R Clapham, M O McClure, J A McKeating, A McKnight, A G Dalgleish, Q J Sattentau, J N Weber.   

Abstract

The envelope glycoproteins of HIV, gp120 and gp41, contain epitopes recognized by neutralizing antibodies. Studies of human sera from infected individuals indicate that group-specific neutralization antigens common to most isolates of HIV-1 exist, and that some HIV-2 antisera cross-neutralize HIV-1. Neutralization epitopes for HIV-1 have been identified and mapped, including a group-specific antigen on gp41, and a type-specific antigen on gp120. Neutralization "escape" mutants have been selected in vitro with a neutralizing mab to the type-specific antigenic loop. The CD4 antigen binds HIV-1 gp120 with high affinity and acts as the receptor on human and simian T-lymphocytes and monocytes for all strains of HIV-1, HIV-2, and SIV tested. Following binding to the CD4 receptor, HIV becomes internalized by a pH-independent process. The principle binding domain for gp120 is located in the N-terminal V domain of CD4. Anti-idiotypic sera to CD4 mabs recognizing the same site weakly neutralize HIVs of many strains, and soluble, recombinant forms of CD4 strongly neutralize HIV. Neither anti-CD4 mabs nor sCD4 inhibit the low level of plating of HIV observed on tumour cells in culture of glial (brain) and muscle origin, indicating that CD4 is not essential for infection of these cell types.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2465401

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  10 in total

1.  The tailless icosahedral membrane virus PRD1 localizes the proteins involved in genome packaging and injection at a unique vertex.

Authors:  Brent Gowen; Jaana K H Bamford; Dennis H Bamford; Stephen D Fuller
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

2.  Markers for HIV-disease progression in untreated patients and patients receiving AZT: evaluation of viral activity, AZT resistance, serum cholesterol, beta 2-microglobulin, CD4+ cell counts, and HIV antigen.

Authors:  H Rübsamen-Waigmann; B Schröder; L Biesert; C D Bauermeister; H von Briesen; H Suhartono; F Zimmermann; H D Brede; A Regeniter; S Gerte
Journal:  Infection       Date:  1991       Impact factor: 3.553

3.  Determining the frequency and mechanisms of HIV-1 and HIV-2 RNA copackaging by single-virion analysis.

Authors:  Kari A Dilley; Na Ni; Olga A Nikolaitchik; Jianbo Chen; Andrea Galli; Wei-Shau Hu
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

4.  Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization.

Authors:  J E Hansen; H Clausen; C Nielsen; L S Teglbjaerg; L L Hansen; C M Nielsen; E Dabelsteen; L Mathiesen; S I Hakomori; J O Nielsen
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

5.  A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.

Authors:  E J Park; M K Gorny; S Zolla-Pazner; G V Quinnan
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

6.  Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor.

Authors:  C M Hill; H Deng; D Unutmaz; V N Kewalramani; L Bastiani; M K Gorny; S Zolla-Pazner; D R Littman
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

7.  Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection.

Authors:  L D Giavedoni; V Planelles; N L Haigwood; S Ahmad; J D Kluge; M L Marthas; M B Gardner; P A Luciw; T D Yilma
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

8.  Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality.

Authors:  David Beauparlant; Peter Rusert; Carsten Magnus; Claus Kadelka; Jacqueline Weber; Therese Uhr; Osvaldo Zagordi; Corinna Oberle; Maria J Duenas-Decamp; Paul R Clapham; Karin J Metzner; Huldrych F Günthard; Alexandra Trkola
Journal:  PLoS Pathog       Date:  2017-03-06       Impact factor: 6.823

Review 9.  Lentiviral Vectors for Ocular Gene Therapy.

Authors:  Yvan Arsenijevic; Adeline Berger; Florian Udry; Corinne Kostic
Journal:  Pharmaceutics       Date:  2022-07-31       Impact factor: 6.525

10.  HIV-1 autologous antibody neutralization associates with mother to child transmission.

Authors:  Elly Baan; Anthony de Ronde; Martijn Stax; Rogier W Sanders; Stanley Luchters; Joseph Vyankandondera; Joep M Lange; Georgios Pollakis; William A Paxton
Journal:  PLoS One       Date:  2013-07-17       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.